Suboxone was the first iteration of a new treatment approach to opioid dependence. Just as beta blocker producers developed drugs with differences in selectivity, duration of effect, and other features, buprenorphine/naloxone products will be developed for a range of niche markets and medical conditions. Already, bio-availability of buprenorphine has been doubled with Bunavail compared to Suboxone film, resulting in a reduction in constipation caused by norbuprenorphine. Stay tuned for updates on this developing area of medicine.
The web site of Reckitt-Benckiser, maker (for now) of Suboxone Film. In November of 2014 Reckitt announced the spin-off of their pharmaceutical division to a new company, to be called Indivior.
A buprenorphine/naloxone product manufactured by Orexo. Zubsolv has a bioavailability of about 40% compared to Suboxone Film’s 25%-30%.
A product released in November of 2014 from BioDelivery Sciences, consisting of a buprenorphine/naloxone delivery system called ‘BEMA’ that yields a buprenorphine bioavailability of 50%.